Adverse effects and perceived benefits of medications in children with chronic noncancer pain
Abstract
Background: There has been limited research in assessing the risk-benefit profile of pharmacological interventions for pediatric chronic pain.
Aims: This quality-improvement analysis evaluated the incidence of adverse effects within the first month of initiating pharmacologic therapy in children and adolescents with chronic non-cancer pain receiving pharmacological treatment. In addition, we assessed perceived benefits of pharmacologic interventions during the same period.
Methods: We included pediatric patients with chronic primary or secondary pain enrolled in tertiary care interdisciplinary pain program. The primary endpoint was the proportion of patients reporting adverse effects within four weeks of starting a new medication (antiepileptics, antidepressants, nonsteroidal anti-inflammatory drugs, Tramadol or other drugs). Patients were provided with a tabulated adverse effects (5% or higher) for each medication they were receiving. We quantified the incidence of adverse effects, but severity of the adverse effects, causality or pharmacological interactions were not assessed. The secondary outcome was the proportion of patients reporting benefit as a dichotomous variable (Yes or No) in pain, sleep, physical function and mood. Each domain was treated as an independent, non-composite variable without graded scales.
Results: 142 patients aged 7-17 with chronic, predominantly female (90%) received 291 prescriptions (mean 2.0 per patient). Adverse effects occurred in 115/142…
Read the paper
Related studies
- Tryptophan Metabolism and Gut-Brain Homeostasis
- Rationale for a Multi-Factorial Approach for the Reversal of Cognitive Decline in Alzheimer’s Disease and MCI: A Review
- Prioritized Research for the Prevention, Treatment, and Reversal of Chronic Disease: Recommendations From the Lifestyle Medicine Research Summit
- Relationship between sleep disorders and gut dysbiosis: what affects what?
- The role of CLOCK gene in psychiatric disorders: Evidence from human and animal research
- Genetic, Transcriptome, Proteomic, and Epidemiological Evidence for Blood-Brain Barrier Disruption and Polymicrobial Brain Invasion as Determinant Factors in Alzheimer’s Disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.